CEL-SCI (NYSE: CVM) raises about $10M in new common stock sale

Rhea-AI Filing Summary

CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC for a registered direct offering of 1,111,200 shares of common stock at $9.00 per share. The offering closed on August 29, 2025, generating gross proceeds of approximately $10,000,800 before fees and expenses. CEL-SCI plans to use the net proceeds to continue developing its Multikine program, as well as for general corporate purposes and working capital.

The company will pay the placement agent a 7.0% cash fee on gross proceeds and reimburse certain expenses up to $185,000. For 30 days after closing, CEL-SCI agreed not to issue or register additional equity securities, subject to exceptions, and its directors and officers agreed to 45-day lock-ups on sales or transfers of company securities. The shares were sold under an effective Form S-3 shelf registration and related prospectus supplement.

Insights

Equity Capital Markets Analyst

CEL-SCI raises about $10M in new equity, adding near-term dilution but strengthening cash resources.

CEL-SCI completed a registered direct equity offering of 1,111,200 common shares at $9.00 per share, for $10,000,800 in gross proceeds. This type of transaction increases the share count but provides immediate cash without adding debt. The shares were issued under an effective Form S-3 shelf registration with a prospectus supplement dated August 27, 2025.

Net proceeds, after a 7.0% placement fee and up to $185,000 of reimbursed expenses, are earmarked to fund continued development of Multikine, plus general corporate purposes and working capital. Short lock-up periods apply: 30 days restricting new company issuances or registrations (with exceptions) and 45 days restricting director and officer sales. The overall impact depends on how effectively CEL-SCI deploys this capital into its development pipeline.

0000725363false00007253632025-08-272025-08-27iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 27, 2025

CEL-SCI CORPORATION

(Exact name of Registrant as specified in its charter)

Colorado		001-11889		84-0916344
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

8229 Boone Blvd. #802

Vienna, VA 22182

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (703) 506-9460

N/A

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.01 per share		CVM		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On August 27, 2025, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into a Placement Agency Agreement with ThinkEquity LLC (the “Placement Agent”) relating to the sale and issuance of 1,111,200 shares of the Company’s common stock, at an offering price of $9.00 per share (the “Shares”).

The Offering closed on August 29, 2025.  The gross proceeds from the Offering were approximately $10,000,800 before deducting Placement Agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering to fund the continued development of Multikine, for general corporate purposes, and working capital.

The securities were offered and sold by the Company pursuant to the Company’s effective registration statement on Form S-3 (Registration No. 333-288515) which was declared effective by the Securities Exchange and Commission (the “SEC”) on August 12, 2025, the base prospectus included therein, as amended and supplemented by the prospectus supplement dated August 27, 2025.

Pursuant to the terms of the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the gross proceeds of the Offering and to reimburse the Placement Agent for certain of its expenses (including fees and expenses of its legal counsel) in an aggregate amount up to $185,000. The Company further agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for a period of 30 days from the closing of this offering, subject to certain exceptions. Additionally, each of the directors and officers of the Company, pursuant to lock-up agreements, agreed not to sell or transfer any of the Company securities which they hold, subject to certain exceptions, for a period of 45 days from the closing of this offering.

The Placement Agency Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Placement Agent, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The foregoing description of the Placement Agency Agreement is not complete and is qualified in its entirety by reference to the full text of the Placement Agency Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

2

Item 8.01 Other Events.

On August 27, 2025, the Company issued a press release announcing the pricing of the Offering, which press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On August 29, 2025, the Company issued a press release announcing the closing of the Offering. A copy of this press release is attached as Exhibit 99.2.

The information in this Item 8.01, including Exhibit 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act  or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Certain of the statements made in this Current Report on Form 8-K are forward looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by the Company is contained under the caption “Risk Factors” in the Company’s prospectus supplement filed with the SEC on August 27, 2025 pursuant to Rule 424(b)(5) promulgated under the Securities Act, the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 filed with the SEC on January 13, 2025, and other filings made by the Company with the SEC, all of which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
1.1		Placement Agency Agreement dated August 27, 2025, by and between CEL-SCI Corporation and ThinkEquity, LLC
5.1		Opinion of Hart & Hart, LLC
23.1		Consent of Hart & Hart, LLC (included in Exhibit 5.1)
99.1		Press Release dated August 27, 2025
99.2		Press Release dated August 29, 2025

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 29, 2025

	CEL-SCI CORPORATION
	By:	/s/ Geert Kersten
		Geert Kersten
		Chief Executive Officer

4

FAQ

What equity offering did CEL-SCI (CVM) complete in August 2025?

CEL-SCI completed a registered direct offering of 1,111,200 shares of its common stock at an offering price of $9.00 per share, under an effective Form S-3 shelf registration and an August 27, 2025 prospectus supplement.

How much cash did CEL-SCI raise in this stock offering?

The transaction generated gross proceeds of approximately $10,000,800 before deducting placement agent fees and other offering expenses payable by CEL-SCI.

How will CEL-SCI use the proceeds from the August 2025 offering?

CEL-SCI intends to use the net proceeds from the offering to fund the continued development of Multikine, and for general corporate purposes and working capital.

What fees will CEL-SCI pay to the placement agent ThinkEquity?

Under the Placement Agency Agreement, CEL-SCI agreed to pay ThinkEquity a cash fee equal to 7.0% of the gross proceeds of the offering and to reimburse certain expenses, including legal fees, in an aggregate amount up to $185,000.

Are there any lock-up or issuance restrictions following CEL-SCI’s offering?

For 30 days from the closing of the offering, CEL-SCI agreed not to issue or agree to issue most additional equity or file registration statements, subject to exceptions. In addition, each director and officer agreed, via lock-up agreements, not to sell or transfer company securities they hold for 45 days from the closing, subject to certain exceptions.

Under what registration statement were CEL-SCI’s new shares sold?

The shares were offered and sold pursuant to CEL-SCI’s effective shelf registration statement on Form S-3 (Registration No. 333-288515), which was declared effective by the SEC on August 12, 2025, and a related base prospectus and prospectus supplement dated August 27, 2025.